Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Earnings and Valuation
This table compares Ensysce Biosciences and Scienture”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ensysce Biosciences | $5.07 million | 1.62 | -$10.18 million | ($2.76) | -0.15 |
| Scienture | $430,000.00 | 29.10 | -$41.51 million | ($2.10) | -0.15 |
Profitability
This table compares Ensysce Biosciences and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ensysce Biosciences | -280.53% | -2,550.30% | -320.49% |
| Scienture | N/A | -53.51% | -42.47% |
Volatility and Risk
Ensysce Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500.
Insider & Institutional Ownership
5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for Ensysce Biosciences and Scienture, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ensysce Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
Scienture has a consensus target price of $1.50, suggesting a potential upside of 392.29%. Given Scienture’s stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than Ensysce Biosciences.
Summary
Scienture beats Ensysce Biosciences on 12 of the 14 factors compared between the two stocks.
About Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
